Jump to main content
Jump to site search


Cocrystals of zonisamide: physicochemical characterization and sustained release solid forms

Abstract

We report four cocrystals of an antiepileptic drug, zonisamide (ZNS), which encounters half-life fluctuation when administered adjunctly with other antiepileptic drugs. Single crystals for two of the novel cocrystals of ZNS were successfully prepared from solvent evaporation experiments and crystal structures were determined. Pharmaceutically acceptable cocrystals were analyzed for their dissolution rate, solubility and stability to draw conclusions on the impact of cocrystallization on physicochemical properties of ZNS. It was found that the cocrystals showed lower solubility and dissolution rate and offer potential benefits in the development of sustained release formulations of ZNS which could address issues with its half-life fluctuation. Recent attempts to explore newer therapeutic applications have suggested ZNS as a potential drug for weight loss management. In this regard, the cocrystal of ZNS with caffeine, which has also been used in the weight loss management, promises potential applications in the development of a novel fixed-dose combination drug which could offer synergistic therapeutic benefits in the treatment of obesity.

Back to tab navigation

Supplementary files

Publication details

The article was received on 19 Jan 2018, accepted on 17 Apr 2018 and first published on 17 Apr 2018


Article type: Paper
DOI: 10.1039/C8CE00084K
Citation: CrystEngComm, 2018, Accepted Manuscript
  •   Request permissions

    Cocrystals of zonisamide: physicochemical characterization and sustained release solid forms

    S. Aitipamula, J. Cadden and P. S. Chow, CrystEngComm, 2018, Accepted Manuscript , DOI: 10.1039/C8CE00084K

Search articles by author

Spotlight

Advertisements